Feasibility, efficacy, and safety of core needle biopsy as a first-line method for cervical lymphadenopathy
European Radiology · 2024
DOI: 10.1007/s00330-024-11174-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Radiology, 2024. Verfasst von Chan Yeop Jeong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea. Hauptthemen laut MEDLINE: Lymphadenopathy, Ultrasonography, Interventional, Image-Guided Biopsy, Lymph Nodes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: This study aimed to determine the feasibility, diagnostic efficacy, and safety of ultrasound-guided core needle biopsy (CNB) as a first-line biopsy method for cervical lymphadenopathy of non-thyroid origin. MATERIALS AND METHODS: This retrospective cohort study included consecutive patients with cervical lymphadenopathy in whom US-guided CNB was used as the first-line biopsy method for cervical lymph nodes (LNs) of presumed non-thyroid origin. The coaxial CNB technique was routinely used, while the tilting and hydrodissection CNB techniques were selectively employed for small high-risk LNs. The primary endpoint of this study was the diagnostic efficacy of CNB, evaluated by the rate of inconclusive results (nondiagnostic and indeterminate) and diagnostic accuracy (criterion 1: malignant results; criterion 2: malignant or indeterminate result). The secondary outcomes included the feasibility and safety of CNB, assessed based on the technical success rate and complication rate, respectively. RESULTS: The rates of nondiagnostic, indeterminate, and inconclusive results were 0.7%, 3.4%, and 4.1%, respectively. The sensitivity, specificity, and accuracy of CNB for malignant LNs were 96.2%, 100%, and 97.8%, respectively, with criterion 1, and these values were all 99.8% with criterion 2. The technical success rate of CNB was 99.3%. There were no major complications and 7 cases (0.6%) of minor complications (asymptomatic hematomas). CONCLUSION: CNB was technically feasible, effective, and safe as a first-line biopsy method for cervical lymphadenopathy of non-thyroid origin with high diagnostic accuracy for malignant nodal disease. KEY POINTS: Question The role of US-guided CNB as a first-line biopsy method for cervical LNs has not yet been verified and established. Findings US-guided CNB, as a first-line method, demonstrated a high technical success rate and diagnostic accuracy for malignant nodes, with few minor complications. Clinical relevance US-guided CNB can be used as an effective first-line biopsy method for cervical lymphadenopathy and will enable accurate diagnosis of malignant LNs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea.
- Department of Pathology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea.
- Department of Radiology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea. nndgna@gmail.com.
Zitieren
APA
Jeong, C. Y., Noh, B. J., & Na, D. G. (2024). Feasibility, efficacy, and safety of core needle biopsy as a first-line method for cervical lymphadenopathy. European Radiology. https://doi.org/10.1007/s00330-024-11174-9
Vancouver
Jeong CY, Noh BJ, Na DG. Feasibility, efficacy, and safety of core needle biopsy as a first-line method for cervical lymphadenopathy. European Radiology. 2024. doi:10.1007/s00330-024-11174-9
BibTeX
@article{Jeong2024,
author = {Jeong, Chan Yeop and Noh, Byeong-Joo and Na, Dong Gyu},
title = {Feasibility, efficacy, and safety of core needle biopsy as a first-line method for cervical lymphadenopathy},
journal = {European Radiology},
year = {2024},
doi = {10.1007/s00330-024-11174-9}
}
EUVIMED